Molecular docking experiments showed that ESPL1 had a high molecular affinity for paclitaxel (−10.0 kcal/mol) and gemcitabine (−6.8 kcal/mol), suggesting that these drugs play vital roles in treating BC (Fig. 9C). This evidence concerns the gene ESPL1 and breast cancer.